Business
Appointment of Broker
Appointment of Broker.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n3 June 2011\n\n Scancell Holdings Plc \n\n (`Scancell Holdings' or the `Company') \n\n Appointment of Broker \n\nScancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer\nvaccines is pleased to announce the appointment of XCAP Securities plc as\nBroker, with immediate effect.\n\nFor further information contact:\n\nScancell Holdings plc Tel: +44 (0) 207 245 1100 \n \nProfessor Lindy Durrant \n \nwww.scancell.com \n \nZeus Capital Tel: +44 (0) 161 831 1512 \n \nNominated Advisor \n \nRoss Andrews/ Tom Rowley \n \nXCAP Securities plc Tel: +44 (0)20 7101 7070 \n \nBroker \n \nJohn Belliss / Parimal Kumar \n \nHansard Communications Ltd Tel: +44 (0)20 7245 1100 \n \nAdam Reynolds / Guy McDougall \n\nAbout Scancell\n\nScancell is developing novel therapeutic vaccines for the treatment of cancer\nand infectious diseases based on its groundbreaking ImmunoBody® technology\nplatform. Scancell's first cancer vaccine SCIB1, which entered clinical trials\nin 2010, is being developed for the treatment of melanoma.\n\nTreating cancer by vaccination allows small non-toxic doses of a vaccine to be\nadministered to a patient, stimulating an immune response. Effective cancer\nvaccines need to target dendritic cells to stimulate both parts of the cellular\nimmune system; the helper cell system where inflammation is stimulated at the\ntumour site; and the cytotoxic T-lymphocyte or CTL response where immune system\ncells are primed to recognise and kill specific cells.\n\nA limitation of many cancer vaccines currently in development is that they\ncannot specifically target dendritic cells in vivo. Several groups have\ndemonstrated successful vaccination by growing dendritic cells ex vivo, pulsing\nthem with tumour antigens and re-infusing them. However, this procedure is\npatient specific, time consuming and expensive. Scancell has developed its\nbreakthrough patent protected ImmunoBody® technology to overcome these\nlimitations.\n\nAn ImmunoBody® is a human antibody or fusion protein engineered to express\nhelper cell and CTL epitopes from tumour antigens over-expressed by cancer\ncells. Antibodies are ideal vectors for carrying T cell epitopes from tumour\nantigens as they have long half-lives and can effectively target dendritic\ncells via their Fc receptors, allowing efficient stimulation of both helper and\nCTL responses.\...